Antonio Passaro, Medical Oncologist and a Medical Director with High Specialization Assignment at the European Institute of Oncology, shared a post on LinkedIn:
“Proud to share our newly published Comment in The Lancet Oncology, co-authored with Xiuning Le.
ADAURA and ARTS have irreversibly changed the landscape of resected EGFR-mutant NSCLC, establishing adjuvant EGFR inhibition as a global standard of care. The key question is no longer whether this strategy works, but how to deploy it optimally.
In this piece, we argue that the next paradigm shift will come from integrating ctDNA-based minimal residual disease into adjuvant decision-making. Moving beyond anatomical staging alone, MRD has the potential to guide treatment intensity and duration, aligning adjuvant therapy with true biological risk and bringing precision oncology into the curative setting.
From fixed strategies to biology-driven adaptation: this is where early-stage EGFR-mutant NSCLC is heading.”
Title: Precision oncology in resected EGFR-mutant NSCLC
Authors: Antonio Passaro, Xiuning Le
